Hologic revenue warning hurts stock
Investors sold shares of bone densitometry company Hologic last month after the Waltham, MA, firm announced that it expected lower revenues for its first quarter (end-December). Hologic on Dec. 23 told investors that it expected first-quarter sales of
Investors sold shares of bone densitometry company Hologic last month after the Waltham, MA, firm announced that it expected lower revenues for its first quarter (end-December). Hologic on Dec. 23 told investors that it expected first-quarter sales of about $25 million, down slightly compared with $27.1 million in the same period a year ago.
The news prompted a sell-off in Hologic stock, with the company's shares dropping from $25.38 on Dec. 22 to $20.81 on Dec. 23, a drop of 18%. Hologic said that two-thirds of its x-ray bone densitometer sales were of its older QDR 1000plus model, which has lower prices and margins compared with the company's Acclaim densitometer series. QDR 1000plus sales are up, due to Hologic's increased penetration of the primary-care market that has resulted from relationships such as the one it has forged with Physician Sales and Service.
Several other bone densitometry companies reported revenue shortfalls in 1997 due to confusion over Medicare reimbursement rates for bone densitometry (SCAN 11/12/97). Hologic said that it is comfortable with analysts' estimates projecting the company's performance through its year end in September.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
